Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3911
Source ID: NCT06478550
Associated Drug: Semaglutide
Title: A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment
Acronym:
Status: ACTIVE_NOT_RECRUITING
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Semaglutide
Outcome Measures: Primary: Persistency of semaglutide s.c. treatment in PSS app with connectivity vs control arm (Yes/No) (HCP reported), Measured as number of participants (Yes/No)., At Visit 2 (week 16) | Secondary: Time from first dose to discontinuation (HCP reported), Measured in days., From Visit 1 (week 0) to Visit 2 (week 16)|HCP prespecified maintenance dose achieved at V2 (week 16), Measured as number of participants (Yes/No)., At visit 2 (week 16)|Time to HCP prespecified maintenance dose (HCP reported), Measured in days., From Visit 1 (week 0) to Visit 2 (week 16)
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 304
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2024-06-26
Completion Date: 2025-04-09
Results First Posted:
Last Update Posted: 2025-04-09
Locations: University Hospital of Athens ATTIKON, Athens, Attica, 12462, Greece|General Hospital Of Thessaloniki Papageorgiou, Thessaloniki, Nea Efkarpia, 56429, Greece|"Laiko" General Hospital of Athens, Goudi/Athens, 11527, Greece|Univ Gen Hospital Larisa, Endocrinology & Metabolic Disease, Larissa, 41110, Greece|Tzaneio General Hospital of Piraeus, Piraeus, 18536, Greece|General Hospital of Thessaloniki 'G. Gennimatas, Thessaloniki, 54635, Greece
URL: https://clinicaltrials.gov/show/NCT06478550

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress